Tesaglitazar Reduced the Prevalence of Metabolic Syndrome and Impaired Fasting Glucose in an Insulin-Resistant, Non-Diabetic Population

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 54; p. A152
Main Authors Schuster, H M, Fagerberg, B, Edwards, S, Halmos, T
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 01.06.2005
Online AccessGet full text

Cover

More Information
ISSN:0012-1797
1939-327X